| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Cash flows from financing activities | -75.6 | -121.2 |
| Effect of exchange rate changes on cash and cash equivalents | 0 | 0.2 |
| Change in cash, cash equivalents and restricted cash | 107.2 | 31 |
| Cash and cash equivalents at beginning of period | 241 | - |
| Cash and cash equivalents at end of period | 348.2 | - |
NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX)